TuesdayFeb 12, 2013 11:53 am

Chinese Cyber Attacks Change the Game

As long as there have been human conflicts, there has been spying, the penetration of secrecy to discover the plans and tools of the other side. For most of history, spying was based almost exclusively on physical infiltration, getting human eyes, ears, and hands inside the opponent’s wall, or capturing and decoding physical messages. The development of electronic and radio communication added a new level to the game, allowing messages to be intercepted over the wire or out of the air. But never has the access to critical information been as profound or far-reaching as it is today. Digital electronics…

Continue Reading

TuesdayFeb 12, 2013 7:42 am

Dr. Thomas Reynolds Joins MEI Pharma, Inc. (MEIP) Board of Directors

Yesterday, MEI Pharma announced that it has appointed Thomas C. Reynolds, M.D., Ph.D., to its Board of Directors. An industry veteran, Dr. Reynolds brings over 20 years of oncology drug development experience to MEI, including direct oversight in the development and approval of the hematologic cancer drug ADCETRIS. “I am delighted to join the Board of MEI Pharma at such an exciting time for the company,” said Dr. Reynolds. “I believe that MEI Pharma is poised to make an immediate impact in the oncology arena with its lead drug candidate, Pracinostat. I look forward to working closely with the rest…

Continue Reading

TuesdayFeb 12, 2013 7:42 am

International Stem Cell Corp. (ISCO) Metabolic Liver Disease Study Shows Solid Efficacy and Safety Results in Robust, Established Animal Model

International Stem Cell, the biotech developer of a powerful human parthenogenetic stem cell (hpSC) technology platform which yields pluripotent cells from unfertilized eggs that can be immune-matched to millions of humans irrespective of sex and racial genetic makeup, reported conclusions from their efficacy/safety study of hpSC-derived hepatocyte-like cells (HLCs) in congenital liver disorder associated with bilirubin metabolism, using a firmly established animal model. The potential for this solution in Criggler-Najjar syndrome type 1 (CN1), a dangerous inherited metabolic disorder of the liver characterized by abnormal buildup of the toxin bilirubin due to the absence of the enzyme UGT1A1, is immense.…

Continue Reading

TuesdayFeb 12, 2013 7:41 am

Cardium Therapeutics, Inc. (CXM) Wound Care Product Awarded Seal of Approval by American Podiatric Medical Association

Today before the opening bell, Cardium Therapeutics announced that the American Podiatric Medical Association (APMA) has granted its prestigious Seal of Approval to Excellagen®, Cardium’s advanced, FDA-cleared wound care product, for improving foot health and mobility. Excellagen is a syringe-based, professional-use, pharmaceutically formulated 2.6% fibrillar Type I bovine collagen gel that functions to activate the wound healing process and accelerate the growth of granulation tissue. Excellagen can be used to treat neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds. APMA, the nation’s leading professional organization for podiatrists, has 53 state component locations across…

Continue Reading

MondayFeb 11, 2013 2:42 pm

Quest Rare Minerals Ltd. (QRM) Updates Markets on Pre-Feasibility Study, Prep Work at High-Density Heavy Rare Earth Deposit

Quest Rare Minerals, which was named Prospector of the Year in 2010 by the Quebec Mineral Exploration Association for the importance of the heavy rare earth element deposit discovered by the company at their Strange Lake property (some 133.4k acres), updated markets today regarding the pre-feasibility study being hammered out for the B-Zone deposit at Strange Lake, as well as other developmental progress associated with this exceptional mineralization. Not only is this project an extremely large, highly-concentrated rare earth site, it has key by-products, like niobium and zirconium, in abundance as well. Overall site design projections call for an easily…

Continue Reading

MondayFeb 11, 2013 2:42 pm

Advanced Cell Technology, Inc. (ACTC) Clinical Partner Gets FDA Approval to Commence Phase I/II Myopia Study

2013 Advanced Cell Technology’s clinical partner, the University of California, Los Angeles (UCLA), has received FDA approval of its Investigator Investigational New Drug (IND) application, providing a green light for UCLA scientists to commence a phase I/II study using ACT’s retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat myopic macular degeneration (myopia), or nearsightedness. Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA’s Jules Stein Eye Institute, will initiate the 12-patient study to evaluate the safety in patients with severe myopia,…

Continue Reading

MondayFeb 11, 2013 2:41 pm

How Viscount Systems Inc. (VSYS) is Securing the Market

There are several key market factors that offer support to the future growth of Viscount Systems, provider of advanced security systems for companies, schools, prisons, hospitals, and multi-family high-rises since 1969. • The security industry is under technological pressure to change, pressures brought on by cost requirements, new information security regulations, legacy systems that badly need updating, and powerful new technologies involving communications and networking. • Existing security systems, based upon aging control panel technology, will become increasingly difficult to upgrade, providing an opportunity for the very few full system providers familiar with IT, cloud, and other options, such as…

Continue Reading

MondayFeb 11, 2013 11:24 am

VIASPACE, Inc. (VSPC) Ships 25 Acres of Giant King Grass to St. Croix

Today before the opening bell, VIASPACE announced that it has harvested a large number of seedlings from its Giant King Grass nursery in California and had them transported in a 40-foot refrigerated container to St. Croix, US Virgin Islands where they have been planted in a 25-acre propagation nursery operated by Tibbar Energy. Tibbar plans to propagate the Giant King Grass to create a 1,000+ acre plantation to fuel the 7 MW anaerobic digestion power plant under construction. According to today’s press release, the Giant King Grass will be ready to propagate within six months.  Tibbar anticipates having the power…

Continue Reading

MondayFeb 11, 2013 11:24 am

XSUNX Inc. (XSNX) Video Chart for Monday, February 11, 2013

XSNX is making a double bottom pattern with pretty solid support established at 1 cent. Volume increased on Friday as the stock price rose 12 percent, putting the chart on watch to possibly challenge the resistance at 1.9 cents. To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts Let us hear your thoughts below:

Continue Reading

MondayFeb 11, 2013 11:23 am

Consorteum Holdings, Inc. (CSRH) Secures $30 Million Funding Commitment from AIC Group Holdings

Consorteum Holdings just announced that it has signed a binding term sheet with AIC Group Holdings Limited for a $30,000,000 funding commitment. A private equity group, AIC Group Holdings Limited is a corporation organized under the laws of the British Virgin Islands. The funding procured from this agreement will provide working capital and allow the company to identify potential merger and acquisitions that will strengthen its ability to compete in the online and mobile gaming market place. Consorteum will focus on its new partnership with Knockout Gaming Inc., an Isle of Man Limited corporation, which has a full online casino…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered